ALMS Now Depends on Whether Regulatory Conviction Matches Management Confidence After That Lupus Miss

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Alumis does not specify an earnings release time in the available data, though the company has historically reported after market close based on prior quarters.

Alumis has exhibited significant volatility around earnings, with an average absolute Day 0 move of 1.87% and an average Day +1 move of 6.98%. The Day +1 range averages 13.34%, indicating substantial post-earnings price swings.

The most recent earnings report in August 2026 saw a Day 0 decline of 4.46%, followed by a Day +1 gain of 3.69%. Prior to that, the May 2026 report showed minimal Day 0 movement but a sharp Day +1 drop of 7.15%. The March 2026 report was relatively quiet, while November 2025 saw a modest Day +1 gain of 4.55%.

The historical pattern suggests investors should prepare for meaningful post-earnings volatility, particularly on the day following the release. Given the company's recent lupus trial miss and the market's heightened focus on the psoriasis NDA timeline, any commentary on regulatory progress or cash burn could drive outsized moves.

Part 2.2: Options Market Expected Move

The options market is pricing a 13.44% expected move for the November 20 expiration, with an implied range of $5.75 to $7.53. This is notably higher than the stock's average historical Day 0 move of 1.87% but roughly in line with the average Day +1 move of 6.98% and well below the average Day +1 range of 13.34%. The elevated implied volatility of 93.58% reflects heightened uncertainty following the September lupus trial miss and the stock's sharp decline. Options traders appear to be pricing in the potential for significant post-earnings movement, consistent with the stock's recent history of double-digit swings.

Part 3: What Analysts Are Saying

Current Analyst Consensus

Alumis holds a Strong Buy consensus among Wall Street analysts, with 9 Strong Buy ratings, 0 Moderate Buys, and 2 Hold ratings. The average price target stands at $31.12, implying 370% upside from the current price of $6.62. Price targets range from a low of $15.00 to a high of $46.00, reflecting wide dispersion in views on the company's risk-reward profile.

Sentiment Trend

Analyst sentiment is classified as unchanged over the past month, with the rating breakdown holding steady at 9 Strong Buys and 2 Holds. However, this stability masks significant underlying shifts. Following the September lupus trial miss, Guggenheim downgraded Alumis from Buy to Neutral, while Oppenheimer slashed its price target from $55 to $37 and Wells Fargo cut its target from $51 to $25. Despite these reductions, most analysts maintained Overweight or Outperform ratings, suggesting the selloff was viewed as overdone relative to the psoriasis opportunity.

Valuation Implications

The consensus price target of $31.12 implies substantial upside, but the stock's current valuation below its cash balance creates a unique dynamic. With Alumis trading at $6.62 and holding over $500 million in cash, the market is effectively assigning negative value to the entire pipeline, including the Phase 3-validated psoriasis program. Analysts appear to believe the market has overreacted to the lupus setback, with the psoriasis NDA submission and potential approval representing a significant re-rating catalyst. However, the wide range of price targets—from $15 to $46—underscores the binary nature of the investment thesis and the uncertainty surrounding regulatory outcomes and future capital needs.

Part 4: Technical Picture

The Barchart Technical Opinion currently reads 88% Sell, down from 100% Sell last week and 100% Sell a month ago. While still firmly in bearish territory, the signal has weakened slightly in recent sessions, reflecting a modest stabilization after the sharp September selloff.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal suggests near-term momentum remains negative, though less extreme than longer timeframes
• Medium-term (100% Sell): Strong sell signal indicates sustained weakness in the intermediate trend following the lupus trial miss
• Long-term (100% Sell): Strong sell signal reflects the stock's steep decline from earlier 2026 highs and deteriorating long-term trend

Trend Characteristics: The signal strength is classified as Strong with direction Weakening, indicating that while the bearish trend remains intact, selling pressure has begun to ease. This suggests the stock may be entering a consolidation phase after the violent September downdraft.

The stock is currently trading at $6.62, positioned above the 5-day ($6.29), 10-day ($6.45), and 20-day ($6.53) moving averages, but below the 50-day ($7.44), 100-day ($16.80), and 200-day ($20.65) moving averages. This configuration—above short-term averages but well below longer-term ones—is typical of a stock attempting to stabilize after a major decline.

The technical setup heading into earnings is cautious but showing early signs of stabilization. The stock has carved out a base above the $6.00 level in recent weeks, with short-term moving averages beginning to flatten. However, the 50-day moving average at $7.44 represents immediate overhead resistance, while the 100-day and 200-day averages remain far above current levels, underscoring the severity of the year-to-date decline.

The weakening sell signal and the stock's ability to hold above short-term moving averages suggest some near-term support, but the overall technical picture remains fragile. Any disappointment on the earnings call—particularly regarding the psoriasis NDA timeline, cash burn, or regulatory feedback on the lupus program—could trigger a retest of recent lows. Conversely, positive commentary on the NDA submission or better-than-expected expense control could provide a catalyst for a relief rally toward the 50-day moving average. Given the elevated options-implied volatility and the stock's history of sharp post-earnings moves, traders should expect heightened price action in the sessions following the report.